文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

PSMA/MRI引导前列腺癌SBRT局灶加量的早期结局与决策后悔

Early Outcomes and Decision Regret Using PSMA/MRI-Guided Focal Boost for Prostate Cancer SBRT.
PubMed 文献 · Pract Radiat Oncol · 2021-10-04

中位随访2.3年,中危78%、高危20%。3年无生化失败生存率中危99%、高危85%,严重泌尿/肠道困扰分别8%和6%,仅4%表达明显决策后悔。

要点

  • PSMA/MRI引导SBRT局灶加量至45 Gy的3年无生化失败生存率中危99%、高危85%。
  • 严重泌尿和肠道困扰分别为8%和6%,与治疗前水平相似。
  • 仅4%患者表达明显决策后悔,89%无后悔。

核心结论

  • PSMA/MRI引导的前列腺SBRT局灶加量显示出有前景的疗效和低毒性。
  • 不足5%的患者对治疗选择表达明显决策后悔。

研究设计与样本

  • 2015年7月至2019年6月在两所机构开展,120例患者接受统一方案的SBRT。
  • 所有患者置入基准标记和水凝胶,并行MRI和PSMA PET扫描。
  • 中位年龄72岁,中位随访2.3年;按NCCN指南78%为中危、20%为高危。
  • 6例患者联合雄激素剥夺治疗。

主要发现

  • 74%患者报告接受SBRT显著影响了其治疗选择。
  • 5例(4%)表达「相当多」(n=4)或「非常」(n=1)后悔,89%无后悔。
  • 「相当多」或「非常」的泌尿或肠道困扰分别见于8%和6%的患者,与治疗前水平相似。
  • 2例出现nadir+2生化失败,均发现骨转移;另1例在nadir+1.7时PSMA PET发现阴茎球部病灶,位于照射野外。
  • 3年估计无生化失败生存率中危组99%、高危组85%。

关键数值与推荐

  • SBRT总剂量36.25 Gy分5次,为低中危前列腺癌最常用方案。
  • 局灶性大体肿瘤体积加量至45 Gy。
  • 生化失败定义包括nadir+2和nadir+1.7(后者经PSMA PET确认)。

临床怎么用

  • PSMA/MRI引导SBRT局灶加量可作为中高危前列腺癌的可行治疗选择,需关注野外复发。
  • 治疗前应充分沟通,多数患者认为SBRT显著影响其治疗选择,决策后悔率低。
  • 泌尿和肠道毒性需长期随访评估,初期结果显示与治疗前相似。

局限性

  • 中位随访仅2.3年,早期疗效和毒性数据尚不成熟。
  • 单臂设计,缺乏随机对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) is a recognized treatment for low- and intermediate-risk prostate cancer, with 36.25 Gy in 5 fractions the most commonly used regimen. We explored the preliminary efficacy, patient recorded toxicity, and decision regret in intermediate- and high-risk prostate cancer receiving SBRT with prostate-specific membrane antigen (PSMA)/magnetic resonance imaging (MRI) guided focal gross tumor volume boost to 45 Gy. METHODS AND MATERIALS: Between July 2015 and June 2019, 120 patients received SBRT across 2 institutions with a uniform protocol. All patients had fiducial markers and hydrogel, MRI and PSMA positron emission tomography (PET) scan. All patients received a questionnaire asking the degree of urinary, bowel, and sexual bother experienced at set time points, including questions about treatment choice and decision regret. RESULTS: One hundred twelve of 120 patients consented. Their median age was 72 years and median follow-up was 2.3 years. As per National Comprehensive Cancer Network guidelines, 78% had intermediate risk and 20% high risk. Androgen deprivation was combined with radiation in 6 patients. Most patients (74%) reported that receiving SBRT significantly influenced their choice of treatment. Five men (4%) expressed "quite a lot" (n = 4) or "very much" regret (n = 1) regarding their choice of treatment, while 89% expressed "no regret." Similar to pretreatment levels, "quite a lot" or "very much" urinary or bowel bother was expressed in 8% and 6% of patients, respectively. Two patients experienced nadir +2 biochemical failure, both found to have bone metastases. A third patient underwent PSMA PET at nadir +1.7 and had disease at the penile bulb, which was out of field. Three year estimated freedom from biochemical failure was 99% for intermediate and 85% for high-risk groups. CONCLUSIONS: We have demonstrated promising efficacy and low toxicity with PSMA/MRI-guided SBRT focal boost. Less than 5% of patients expressed significant decision regret for their choice of treatment.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Eade T, Kneebone A, Hruby G, et al. Early Outcomes and Decision Regret Using PSMA/MRI-Guided Focal Boost for Prostate Cancer SBRT. Pract Radiat Oncol. 2021. PMID: 34619375. doi:10.1016/j.prro.2021.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。